# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Myelodysplastic syndromes

MYELODYSPLASTIC SYNDROME
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 397 results.
Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)
Status: Not yet recruiting
Last Changed: Jun 14, 2017
First Received: Jun 14, 2017
Disease(s): Myelodysplastic Syndromes
Intervention(s): Allogeneic umbilical cord mesenchymal stem cells, Decitabine
Locations: Inner Mongolia International Mongolian Hospital, Hohhot, Inner Mongolia, China
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
Status: Recruiting
Last Changed: Feb 07, 2019
First Received: Apr 17, 2014
Disease(s): Myelodysplastic Syndrome
Intervention(s): MEDI4736 Evaluate MEDI4736 in MDS, VIDAZA, tremelimumab
Locations: Research Site, Scottsdale, Arizona, United States
Research Site, Los Angeles, California, United States
Research Site, New Haven, Connecticut, United States
Research Site, Tampa, Florida, United States
Research Site, Atlanta, Georgia, United States
... and 20 other locations.
iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes
Status: Not yet recruiting
Last Changed: Jan 14, 2019
First Received: Feb 27, 2018
Disease(s): Myelodysplastic Syndromes
Intervention(s): FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software
Locations: University of Florida, Gainesville, Florida, United States
Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) That Has Relapsed or Refractory to Azanucleosides
Status: Not yet recruiting
Last Changed: Apr 17, 2017
First Received: Feb 20, 2017
Disease(s): Myelodysplastic Syndromes
Intervention(s): Pyrimethamine
Institut Paoli Calmettes Myelodysplastic Syndromes Database
Status: Recruiting
Last Changed: Sep 07, 2017
First Received: Sep 07, 2017
Disease(s): Myelodysplastic Syndromes
Locations: Institut Paoli-Calmettes, Marseille, Paca, France
Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)
Status: Recruiting
Last Changed: Sep 29, 2017
First Received: Oct 11, 2016
Disease(s): Myelodysplastic Syndrome
Intervention(s): GSK2879552, Azacitidine
Locations: GSK Investigational Site, Philadelphia, Pennsylvania, United States
Study of SyB C-1101 in Patients With Myelodysplastic Syndrome
Status: Recruiting
Last Changed: Apr 11, 2018
First Received: Apr 11, 2018
Disease(s): Myelodysplastic Syndrome
Intervention(s): SyB C-1101
Locations: Research Site, Nagoya, Aichi, Japan
Research Site, Maebashi, Gunma, Japan
Research Site, Sapporo, Hokkaido, Japan
Research Site, Kobe, Hyogo, Japan
Research Site, Kurashiki, Okayama, Japan
... and 5 other locations.
CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
Status: Recruiting
Last Changed: Dec 17, 2018
First Received: Jun 28, 2018
Disease(s): Myelodysplastic Syndromes
Intervention(s): CPX-351, Research skin biopsy, Research blood draw, Research bone marrow aspirate
Locations: Moffitt Cancer Center, Tampa, Florida, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients
Status: Recruiting
Last Changed: Oct 23, 2018
First Received: Sep 26, 2013
Disease(s): Myelodysplastic Syndrome
Intervention(s): Antibiotic and antifungal drugs
Locations: S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Azienda Ospedaliera - Nuovo Ospedale 'Torrette', Ancona, Italy
UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro, Bari, Italy
Divisione di Ematologia Ospedale A. Perrin, Brindisi, Italy
ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO, Cagliari, Italy
... and 21 other locations.
Tipifarnib in Subjects With Myelodysplastic Syndromes
Status: Recruiting
Last Changed: Aug 23, 2018
First Received: May 20, 2016
Disease(s): Myelodysplastic Syndromes
Intervention(s): Tipifarnib
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Columbia University Medical Center, New York, New York, United States